News
AOP Orphan Pharmaceuticals announces five-year results on BESREMi® (Ropeginterferon alfa-2b) in Polycythaemia Vera at the American Society of Hematology (ASH) Annual Meeting 2020
7. 12. 2020ICC ruled in favor of AOP Orphan Pharmaceuticals AG in arbitration proceedings pertaining to BESREMi® (Ropeginterferon alpha-2b)
27. 10. 2020Rare disease pioneer AOP Orphan takes over two health care companies, strengthening its position in Europe as well as Vienna as a research- and business hub.
12. 10. 2020
Meet Us Globally
Show more
From the Concept to the Drug
AOP Orphan team covers all essential aspects of product development, starting with preclinical research & toxicology, extending to pharmaceutical & clinical development, including regulatory affairs, quality management & pharmacovigilance.
Partnering
Partnering is of key importance for AOP Orphan. It allows further developing AOP Orphan’s rare disease portfolio and enables to approach patients beyond company’s core markets in Europe.
Join AOP Orphan
AOP Orphan team develops and investigates therapy options for patients with rare diseases – commitment and appreciation are the essence of our cooperative work.